<img alt="" src="https://secure.hero6bell.com/211997.png" style="display:none;">
Investor relations

Board of directors

Peter Ehrenheim

Chairman of the Board
Elected to the board:
September 9, 2019

Operative background from Pharmacia Biotech, Amersham and GE Healthcare. General manager for Separations Division 1999-2006. From 2006-2011 General manager for GE’s Life Sciences Business which was recently acquired by Danaher. From 2011 entrepreneur with different companies and board roles. Presently chairman in Medcap AB, Boule Diagnostics AB and Sophion A/S. Also Director in Biotage AB.

Independence: Independent in relation to the company and the company management, independent in relation to major shareholders.

Kirsti Gjellan

Board director
Elected to the board:
May 18, 2018

More than 30 years of experience from Pharmaceutical industry covering Discovery, Proof of Concept, Pharmaceutical Development, Quality Operations in Manufacturing, EHS, Right First Time/Lean/Six Sigma and site leader management as well as managing director. All work experience has been generated in the dynamic between local and global organizations to create the most business value. Has worked as a Leader/manager and Change Agent since 1989.

Independence: Independent in relation to the company and the company management, independent in relation to major shareholders.

Patrick Van De Velde

Board director
Elected to the board:
June 7, 2017

Current General Manager and Board Member Promega Biotech AB, previous head of marketing Europe at GE Health and sales & business development manager at Sigma Aldrich Sweden.

Independence: Independent in relation to the company and the company management, independent in relation to major shareholders.

Johan Sedihn

Board director
Elected to the board:
May 15, 2020

Johan Sedihn is a Master of Science in Industrial Economics from the Technical University of Linköping. He has more than 25 years of experience in the medical technology industry, most of his time in the Elekta Group. He has been involved in building operations during Elekta's growth in roles such as Executive VP Oncology and Chief Operating Officer. For 13 years, Johan was part of Elekta's Group Management and he was also CEO of subsidiaries in Sweden and the UK, and Chairman of the Board of dozens of subsidiaries around the world. Johan has experience from several board assignments, two of which are currently SyntheticMR AB (publ) where he is chairman of the board and Dirac Research AB where he is a board member. Both of these companies' growth journeys involve similar challenges to those that Bio-Works faces. Johan Sedihn has been living in the UK since 2005.

Independence: Independent in relation to the company and the company management, independent in relation to major shareholders.

Peter Nählstedt

Board director
Elected to the board:
May 15, 2020

Peter Nählstedt has more than 20 years of operative experience from leading positions in life science and industry. He provides consulting services and advisory in business development in the Life Sciences and technology area. During his time as CEO of Probi between 2014-2018 the company grew from 100 MSEK to 600 MSEK. Earlier experience include 4 years at Trelleborg Marine Systems and 8 years at GE Healthcare Life Science of which several years were spent in the US leading its Bioprocess business. Board Director at SenzaGen AB (publ), Chairman of the board at Double Good AB and Supersynbiotics AB.

Independence: Independent in relation to the company and the company management, independent in relation to major shareholders.

Name Title Shares Options or warrants
Peter Ehrenheim Chairman of the Board 82 537 and 654 797 via Färjsundet AB
Kirsti Gjellan Board director 28 456
Patrick Van De Velde Board director 31 100
Johan Sedihn Board director 123 526
Peter Nählstedt Board director 9450
Shareholding information last updated 2021-10-01